Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Trevi Therapeutics Inc
TRVI
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$12.77
-0.06
-0.47%
Ult. Agg.: Oct 22, 4:42 AM
$12.79
-0.04
-0.31%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Trevi Therapeutics Financials
Trevi Therapeutics (TRVI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Trevi Therapeutics Q2 EPS $(0.11), Inline
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 22.22 percent decrease over losses of $(0.09) per share from the same period last year.
Benzinga Newsdesk
PRO
Trevi Therapeutics Q1 EPS $(0.09) Misses $(0.07) Estimate
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is unchanged from the same period last year.
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights
PRO
Trevi Therapeutics Q4 EPS $(0.06) Beats $(0.10) Estimate
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 41.18 percent. This is a 45.45 percent increase over losses of $(0.11) per share
Benzinga Newsdesk
Earnings Scheduled For March 17, 2026
Benzinga Insights
PRO
Trevi Therapeutics Q3 EPS $(0.08) Beats $(0.10) Estimate
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 23.08 percent. This is a 38.46 percent increase over losses of $(0.13) per share
Benzinga Newsdesk
